Latest research on Sildenafil

Sildenfail is a vasoactive agent used to treat erectile dysfunction and reduce symptoms in patients with pulmonary arterial hypertension (PAH). Sildenafil elevates levels of the second messenger, cGMP, by inhibiting its breakdown via phosphodiesterase type 5 (PDE5). PDE5 is found in particularly high concentrations in the corpus cavernosum, erectile tissue of the penis. It is also found in the retina and vascular endothelium. Increased cGMP results in vasodilation which facilitates generation and maintenance of an erection. The vasodilatory effects of sildenafil also help reduce symptoms of PAH.

Latest findings

All patients were given oral Sildenafil (50–100 mg), with a minimum recommended dose of 50 mg and the dosage adjusted according to the parameters of penile blood flow, penile rigidity, and patient compliance. [source, 2016]
After oral Sildenafil administration, the mean IIEF-5 scores for patients with rigidity Grades V, IV, III, and II were 22.04 ± 2.94, 16.33 ± 4.89, 9.67 ± 1.75, and 5.79 ± 0.89, respectively (P < 0.0001, Tables ). [source, 2016]
In these analyses, medication costs were assessed and include any of the eight groups of prescription medications used to possibly treat IPF (corticosteroids, Azathioprine, Cyclophosphamide, N-acetylcysteine, Sildenafil, interferon-gamma, bosentan, etanercept). [source, 2016]
In particular, the efficacy is reported only with whom underwent a nerve-sparing procedure, and Sildenafil is the most efficacious molecule at this regard. [source, 2016]
The rationale of high-dose Sildenafil after RP is the preservation of smooth muscle within the corpora cavernosa with a better return to spontaneous normal erectile function. [source, 2016]
The response rate to Sildenafil treatment for ED after RP in different trials ranges from 35% to 75% among those who underwent nerve-sparing radical prostatectomy and from 0% to 15% among those who underwent non-nerve sparing technique. [source, 2016]
However, the mechanisms responsible for the protective action of the Sildenafil remain to be fully elucidated. [source, 2016]
Sildenafil belongs to a group of drugs known as PDE-5 inhibitors, which enhance intracellular cGMP concentration and activity, thereby improving endothelial function [73]. [source, 2016]
In recent years, Sildenafil has been explored for use in the management of secondary pulmonary hypertension secondary to chronic HF. [source, 2016]
Guazzi and colleagues [74] randomized 44 patients with HFPEF and pulmonary hypertension into the placebo or Sildenafil arm. [source, 2016]